Evidence map›Paper›PMID 37579110›Full record

Trial reportJournal of addiction medicine

Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT.

Marissa Justen, Jennifer Scodes, Martina Pavlicova, Tse-Hwei Choo, Manesh Gopaldas, Angela Haeny, Onumara Opara, Taeho Greg Rhee, John Rotrosen, Edward V Nunes and 2 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Marissa JustenFrom the Yale School of Medicine, New Haven, CT (MJ); Department of Biostatistics, Brown University, Providence, RI (JS); New York Psychiatric Institute, New York, NY (JS); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY (MP); Division of Mental Health Data Science, New York State Psychiatric Institute, New York, NY (T-HC); New York State Psychiatric Institute, New York, NY (MG, OO, EVN); Columbia Irving Medical Center, New York, NY (MG, EVN); Department of Psychiatry, Yale School of Medicine, New Haven, CT (TGR, AH); VA New England Mental Illness, Research, Education, and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT (TGR); NYU Grossman School of Medicine, New York, NY (JR); Department of Emergency Medicine, Yale School of Medicine, New Haven, CT (KH); Yale School of Public Health, New Haven, CT (KH, EJE); Program in Addiction Medicine, Yale School of Medicine, New Haven, CT (KH, EJE); Department of Internal Medicine, Yale School of Medicine, New Haven, CT (EJE).
Jennifer Scodes
Martina Pavlicova
Tse-Hwei Choo
Manesh Gopaldas
Angela Haeny
Onumara Opara
Taeho Greg Rhee
John Rotrosen
Edward V Nunes
Kathryn Hawk
E Jennifer Edelman
National Institute on Drug Abuse · USNew York Psychoanalytic Society and Institute · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
Translational Clinical Research Fellowship on Substance Use DisordersT32DA007294 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Frances Rudnick Levin, Diana M Martinez · 1993 to 2026
$9.3M
NCATS NIH HHS UL1 TR001863NIDA NIH HHS T32 DA007294NIDA NIH HHS U10 DA013046NIDA NIH HHS UG1 DA013035
6 · The paper itself

Abstract

objectiveWe sought to identify the sociodemographic and clinical characteristics associated with homelessnesss, and explore the relationship between homelessnesss and treatment outcomes among Black individuals.

methodsThis is a secondary analysis of the subgroup of Black participants (n = 73) enrolled in "X:BOT," a 24-week multisite randomized clinical trial comparing the effectiveness of extended-release naltrexone versus sublingual buprenorphine-naloxone (n = 570). Outcomes included medication initiation, return to extramedical use of opioids assessed by both self-report and urine toxicology, and engagement in medications for opioid use disorder (MOUD) treatment at 28 weeks postrandomization. Descriptive statistics were performed.

resultsBlack participants were mostly unmarried and male, and about a third were aged 21-30 years. Among people experiencing homelessnesss, more were uninsured (45.5% [10/22] vs 19.6% [10/51]), unemployed (77.3% [17/22] vs 64.7% [33/51]), and reported alcohol (40.9% [9/22] vs 23.5% [12/51]) and sedative use (54.5% [12/22] vs 17.6% [9/51]) within the previous 30 days. Compared with housed Black individuals, a slightly higher proportion of Black individuals experiencing homelessnesss successfully initiated study medication (81.1% [18/22] vs 72.6% [37/51]); similar proportions returned to opioid use during the trial (68.2% [15/22] vs 68.6% [35/51]) and were engaged in MOUD at 28 weeks after trial entry (72.2% [13/18] vs 69.7% [23/33]) among participants located for follow-up.

conclusionsThese descriptive results among Black patients participating in a trial of MOUD suggest that efficacious MOUD is possible despite homelessnesss with additional clinical supports such as those provided by a clinical trial.

Indexed as

Black or African AmericanIll-Housed PersonsOpioid-Related DisordersAdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationFemaleHumansMaleTreatment OutcomeYoung AdultAnalgesics, OpioidBuprenorphine, Naloxone Drug Combination

Identifiers

PMID37579110
PMCPMC10323031
OpenAlexW4318924390

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.